NASDAQ:QNRX

Quoin Pharmaceuticals - QNRX Stock Forecast, Price & News

$4.82

-0.16 (-3.21%)

(As of 08/11/2022 12:00 AM ET)

Add

Compare

Today's Range: $4.69
▼
$5.68
50-Day Range: $3.85
▼
$19.80
52-Week Range: $3.58
▼
$444.00

Volume: 2.28 million shs
Average Volume: 658,277 shs
Market Capitalization: $3.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.00

Quoin Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 937.3% Upside
$50.00 Price Target
Short Interest: Healthy
9.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.50) to ($5.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Quoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.00, Quoin Pharmaceuticals has a forecasted upside of 937.3% from its current price of $4.82.
Amount of Analyst Coverage
Quoin Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
9.30% of the outstanding shares of Quoin Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Quoin Pharmaceuticals has recently decreased by 92.43%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Quoin Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Quoin Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QNRX.

3.1

News and Social Media Coverage

News Sentiment
Quoin Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Quoin Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
41 people have searched for QNRX on MarketBeat in the last 30 days. This is an increase of 215% compared to the previous 30 days.
MarketBeat Follows
27 people have added Quoin Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 575% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 21.72% of the stock of Quoin Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Quoin Pharmaceuticals are expected to grow in the coming year, from ($6.50) to ($5.25) per share.
Price to Book Value per Share Ratio
Quoin Pharmaceuticals has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on QNRX. Maxim Group reduced their price objective on Quoin Pharmaceuticals to $25.00 in a research report on Thursday, May 26th. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research report on Friday, May 6th. They set a "buy" rating and a $25.00 price objective for the company.

Quoin Pharmaceuticals Trading Down 3.2 %

NASDAQ:QNRX traded down $0.16 during midday trading on Thursday, reaching $4.82. 2,277,217 shares of the company traded hands, compared to its average volume of 658,277. Quoin Pharmaceuticals has a twelve month low of $3.58 and a twelve month high of $444.00. The company has a fifty day moving average price of $5.98 and a 200 day moving average price of $11.30.

Quoin Pharmaceuticals (NASDAQ:QNRX - Get Rating) last announced its quarterly earnings results on Monday, May 23rd. The company reported ($2.50) earnings per share (EPS) for the quarter. Equities research analysts predict that Quoin Pharmaceuticals will post -6.5 EPS for the current year.

Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

QNRX Stock News Headlines

August 11, 2022 | finance.yahoo.com

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

August 10, 2022 | americanbankingnews.com

ICU Medical (NASDAQ:ICUI) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Review

August 9, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

August 5, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

August 4, 2022 | investorplace.com

What Is Going on With Quoin Pharmaceuticals (QNRX) Stock?

July 28, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe

July 20, 2022 | americanbankingnews.com

Quoin Pharmaceuticals Stock to Reverse Split on Monday, August 1st (NASDAQ:QNRX)

July 15, 2022 | nasdaq.com

Endo In Deal With Quoin Pharmaceuticals To Develop And Sell Quoin's QRX003 In Canada

July 15, 2022 | finance.yahoo.com

Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

July 15, 2022 | finanznachrichten.de

Endo International plc: Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

July 15, 2022 | finance.yahoo.com

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

July 6, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

July 1, 2022 | investorplace.com

Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?

June 15, 2022 | seekingalpha.com

Quoin Pharmaceuticals gets Nasdaq notification on minimum bid price requirement

June 15, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

June 15, 2022 | seekingalpha.com

Quoin secures licensing & distribution deal for its skin disorder treatments for China

June 15, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China

June 14, 2022 | finance.yahoo.com

Quoin Pharmaceuticals: Strategically Building For Future Success

June 6, 2022 | finance.yahoo.com

Why Are Quoin Pharma Shares Trading Higher Today?

June 6, 2022 | finance.yahoo.com

Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug

May 23, 2022 | finance.yahoo.com

Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University

May 17, 2022 | finance.yahoo.com

Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome

May 11, 2022 | finance.yahoo.com

When Will Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Breakeven?

April 25, 2022 | uk.investing.com

Why Quoin Pharmaceuticals Stock Is Trading Higher

April 25, 2022 | finance.yahoo.com

QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

QNRX Company Calendar

Last Earnings: 5/23/2022
Today: 8/11/2022
Next Earnings (Estimated): 8/23/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:QNRX
CUSIP: N/A
CIK: 1671502
Web: cellect.co
Phone: 972-9974-1444
Fax: 972-9767-8750
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $50.00
High Stock Price Forecast: $100.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +937.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -355.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.67
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.98 per share
Price / Book: 4.92

Miscellaneous

Outstanding Shares: 803,000
Free Float: N/A
Market Cap: $3.87 million
Optionable: Not Optionable
Beta: 1.63

Key Executives

Dr. Michael Myers Ph.D. (Age 60)
Co-Founder, CEO & Chairman
Comp: $1.03M
Ms. Denise Carter (Age 53)
Co-Founder, COO & Director
Comp: $846k
Mr. Gordon Bruce Dunn J.D. (Age 58)
Chief Financial Officer
Comp: $417k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QNRX Stock - Frequently Asked Questions

Should I buy or sell Quoin Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QNRX shares.
View QNRX analyst ratings or view top-rated stocks.
What is Quoin Pharmaceuticals' stock price forecast for 2022?: 3 brokers have issued 1-year target prices for Quoin Pharmaceuticals' shares. Their QNRX share price forecasts range from $25.00 to $100.00. On average, they predict the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 904.0% from the stock's current price.
View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts.
How have QNRX shares performed in 2022?: Quoin Pharmaceuticals' stock was trading at $22.75 on January 1st, 2022. Since then, QNRX shares have decreased by 78.1% and is now trading at $4.98.
View the best growth stocks for 2022 here.
Are investors shorting Quoin Pharmaceuticals?: Quoin Pharmaceuticals saw a drop in short interest in July. As of July 31st, there was short interest totaling 74,700 shares, a drop of 92.4% from the July 15th total of 986,500 shares. Based on an average daily trading volume, of 1,270,000 shares, the days-to-cover ratio is presently 0.1 days.
View Quoin Pharmaceuticals' Short Interest.
When is Quoin Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 23rd 2022.
View our QNRX earnings forecast.

How were Quoin Pharmaceuticals' earnings last quarter?: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) issued its earnings results on Monday, May, 23rd. The company reported ($2.50) earnings per share (EPS) for the quarter.
When did Quoin Pharmaceuticals' stock split?: Shares of Quoin Pharmaceuticals reverse split before market open on Monday, August 1st 2022. The 1-12.5 reverse split was announced on Monday, August 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What is Quoin Pharmaceuticals' stock symbol?: Quoin Pharmaceuticals trades on the NASDAQ under the ticker symbol "QNRX."
How do I buy shares of Quoin Pharmaceuticals?: Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Quoin Pharmaceuticals' stock price today?: One share of QNRX stock can currently be purchased for approximately $4.98.
How much money does Quoin Pharmaceuticals make?: Quoin Pharmaceuticals (NASDAQ:QNRX) has a market capitalization of $3.98 million.
How can I contact Quoin Pharmaceuticals?: Quoin Pharmaceuticals' mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The official website for the company is cellect.co. The company can be reached via phone at 972-9974-1444, via email at ir@cellectbio.com, or via fax at 972-9767-8750.

This page (NASDAQ:QNRX) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Quoin Pharmaceuticals - QNRX Stock Forecast, Price & News

Quoin Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Wall Street Analysts Forecast Growth

Quoin Pharmaceuticals Trading Down 3.2 %

QNRX Stock News Headlines

QNRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

QNRX Stock - Frequently Asked Questions

Should I buy or sell Quoin Pharmaceuticals stock right now?

What is Quoin Pharmaceuticals' stock price forecast for 2022?

How have QNRX shares performed in 2022?

Are investors shorting Quoin Pharmaceuticals?

When is Quoin Pharmaceuticals' next earnings date?

How were Quoin Pharmaceuticals' earnings last quarter?

When did Quoin Pharmaceuticals' stock split?

What is Quoin Pharmaceuticals' stock symbol?

How do I buy shares of Quoin Pharmaceuticals?

What is Quoin Pharmaceuticals' stock price today?

How much money does Quoin Pharmaceuticals make?

How can I contact Quoin Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™